Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 10/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18233674 | 1.00 | CACNA1H (0.49) | CACNA1HDRD2EPHX1CCNT1CDK9 | |
| SCHEMBL18233672 | 1.00 | CACNA1H (0.49) | CACNA1HDRD2EPHX1CCNT1CDK9 | |
| SCHEMBL18233679 | 0.90 | CACNA1H (0.49) | CACNA1HDRD2EPHX1MEN1KMT2A | |
| SCHEMBL20479436 | 0.87 | CACNA1H (0.48) | CACNA1HDRD2EPHX1CCNT1CDK9 | |
| SCHEMBL20480232 | 0.87 | CACNA1H (0.48) | CACNA1HDRD2EPHX1CCNT1CDK9 | |
| SCHEMBL28665379 | 0.87 | CACNA1H (0.48) | CACNA1HDRD2EPHX1CCNT1CDK9 | |
| SCHEMBL31420611 | 0.86 | CACNA1H (0.49) | CACNA1HDRD2EPHX1CCNT1CDK9 | |
| SCHEMBL14197690 | 0.86 | CACNA1H (0.49) | CACNA1HDRD2EPHX1CCNT1CDK9 | |
| SCHEMBL18233684 | 0.85 | DRD2 (0.47) | CACNA1HDRD2EPHX1MEN1KMT2A | |
| SCHEMBL14614740 | 0.84 | CACNA1H (0.53) | CACNA1HDRD2EPHX1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999728-B2 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4267578-A1 | ESTROGEN RECEPTOR MODULATORS | Recurium IP Holdings, LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20220235050-A1 | ESTROGEN RECEPTOR MODULATORS | RECURIUM IP HOLDINGS, LLC | 2022-07-28 | — | — | US | disclosed |
| WO-2022140744-A1 | ESTROGEN RECEPTOR MODULATORS | RECURIUM IP HOLDINGS, LLC (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140744-A1 | ESTROGEN RECEPTOR MODULATORS | RECURIUM IP HOLDINGS, LLC (US) | 2022-06-30 | — | — | WO | disclosed |
| US-11339162-B1 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339162-B1 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3747892-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339162-B1 | Estrogen receptor modulators | ESR2, GPER1, ESRRA | CACNA1H 3698/4885DRD2 4568/4885EPHX1 783/4885 |
| US-11999728-B2 | Estrogen receptor modulators | ESR2, GPER1, ESRRA | CACNA1H 3698/4885DRD2 4568/4885EPHX1 783/4885 |
| US-20220235050-A1 | ESTROGEN RECEPTOR MODULATORS | ESR2, GPER1, ESRRA | CACNA1H 3698/4885DRD2 4568/4885EPHX1 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.